| 000 | 00000cam 2200000zi 4500 |
| 001 | 9.967064 |
| 003 | CaOODSP |
| 005 | 20261102160737 |
| 006 | m o d f |
| 007 | cr cn||||||||| |
| 008 | 261021e202610##onc ob f000 0 eng d |
| 020 | |a9781100010700 |
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
| 043 | |an-cn--- |
| 086 | 1 |aH169-14/2026E-PDF |
| 245 | 00|aGuidance for clinical trials with decentralized elements. |
| 264 | 1|aOttawa ON : |bHealth Canada = Santé Canada, |cOctober 2026. |
| 264 | 4|c©2026 |
| 300 | |a1 online resource (iii, 52 pages) |
| 336 | |atext|btxt|2rdacontent |
| 337 | |acomputer|bc|2rdamedia |
| 338 | |aonline resource|bcr|2rdacarrier |
| 500 | |aTitle from cover. |
| 500 | |aIssued also in French under title: Lignes directrices pour les essais cliniques avec des éléments décentralisés. |
| 500 | |a"Health products." |
| 504 | |aIncludes bibliographical references (pages 50-51). |
| 520 | |a"This guidance outlines regulatory considerations for conducting clinical trials with decentralized elements in Canada. These considerations are supported by Part C, Division 5 of the Food and Drug Regulations (FDR) and the International Council for Harmonisation’s Guideline for Good Clinical Practice (ICH E6)"--Overview, Purpose, page 1. |
| 650 | 0|aDrugs|xTesting|xGovernment policy|zCanada. |
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
| 710 | 1 |aCanada.|bPharmaceutical Drugs Directorate, |eissuing body. |
| 710 | 1 |aCanada. |bBiologic and Radiopharmaceutical Drugs Directorate, |eissuing body. |
| 775 | 08|tLignes directrices pour les essais cliniques avec des éléments décentralisés.|w(CaOODSP)9.967065 |
| 856 | 40|qPDF|s835 KB|uhttps://publications.gc.ca/collections/collection_2026/sc-hc/H169-14-2026-eng.pdf |
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/clinical-trials-decentralized-elements.html |